Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

322 ARTÍCULOS , VIENDO DEL 166 AL 180

Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease

Medina M, Avila J.

Curr Pharm Des. 2010;16(25):2790-8. doi: 10.2174/138161210793176581.

Structural determinants of the multifunctional profile of dual binding site acetylcholinesterase inhibitors as anti-Alzheimer agents

Galdeano C, Viayna E, Arroyo P, Bidon-Chanal A, Blas JR, Muñoz-Torrero D, Luque FJ.

Curr Pharm Des. 2010;16(25):2818-36. doi: 10.2174/138161210793176536.

Review: omega-3 and memory function: to eat or not to eat

Itua I, Naderali EK.

Am J Alzheimers Dis Other Demen. 2010 Sep;25(6):479-82. doi: 10.1177/1533317510376943. Epub 2010 Aug 11.

Inaccuracy in clinical trials: effects and methods to control inaccuracy

Kobak KA.

Curr Alzheimer Res. 2010 Nov;7(7):637-41. doi: 10.2174/156720510793499057.

Why so few drugs for Alzheimer's disease? Are methods failing drugs?

Becker RE, Greig NH.

Curr Alzheimer Res. 2010 Nov;7(7):642-51. doi: 10.2174/156720510793499075.

Cognitive stimulation therapy in the treatment of neuropsychiatric symptoms in Alzheimer's disease: a randomized controlled trial

Niu YX, Tan JP, Guan JQ, Zhang ZQ, Wang LN.

Clin Rehabil. 2010 Dec;24(12):1102-11. doi: 10.1177/0269215510376004. Epub 2010 Aug 16.

The role of tumor necrosis factor-alpha in cognitive improvement after peroxisome proliferator-activator receptor gamma agonist pioglitazone treatment in Alzheimer's disease

Hanyu H, Sato T, Sakurai H, Iwamoto T.

J Am Geriatr Soc. 2010 May;58(5):1000-1. doi: 10.1111/j.1532-5415.2010.02841.x.

The inhibitory effects of different curcuminoids on β-amyloid protein, β-amyloid precursor protein and β-site amyloid precursor protein cleaving enzyme 1 in swAPP HEK293 cells

Liu H, Li Z, Qiu D, Gu Q, Lei Q, Mao L.

Neurosci Lett. 2010 Nov 19;485(2):83-8. doi: 10.1016/j.neulet.2010.08.035. Epub 2010 Aug 18.

Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions

Klaver DW, Wilce MC, Cui H, Hung AC, Gasperini R, Foa L, Small DH.

Biol Chem. 2010 Aug;391(8):849-59. doi: 10.1515/BC.2010.089.

Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study

Gold M, Alderton C, Zvartau-Hind M, Egginton S, Saunders AM, Irizarry M, Craft S, Landreth G, Linnamägi U, Sawchak S.

Dement Geriatr Cogn Disord. 2010;30(2):131-46. doi: 10.1159/000318845. Epub 2010 Aug 21.

Goal-oriented cognitive rehabilitation for people with early-stage Alzheimer disease: a single-blind randomized controlled trial of clinical efficacy

Clare L, Linden DE, Woods RT, Whitaker R, Evans SJ, Parkinson CH, van Paasschen J, Nelis SM, Hoare Z, Yuen KS, Rugg MD.

Am J Geriatr Psychiatry. 2010 Oct;18(10):928-39. doi: 10.1097/JGP.0b013e3181d5792a.

The development of new therapeutics for Alzheimer's disease

Carter MD, Simms GA, Weaver DF.

Clin Pharmacol Ther. 2010 Oct;88(4):475-86. doi: 10.1038/clpt.2010.165. Epub 2010 Sep 1.

The time has arrived to meet the challenge of Alzheimer's disease in Europe

Jones RW.

J Nutr Health Aging. 2010 Aug;14(7):523-4. doi: 10.1007/s12603-010-0262-z.

Evolving attitudes to Alzheimer's disease among the general public and caregivers in Europe: findings from the IMPACT survey

Wortmann M, Andrieu S, Mackell J, Knox S.

J Nutr Health Aging. 2010 Aug;14(7):531-6. doi: 10.1007/s12603-010-0264-x.

The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease

Farlow MR, Grossberg G, Gauthier S, Meng X, Olin JT.

Curr Med Res Opin. 2010 Oct;26(10):2441-7. doi: 10.1185/03007995.2010.513849.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias